Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Retatrutide is currently advancing through Phase 3 clinical trials while it awaits FDA approval
(NEJM, 2023) reported that Retatrutide (8mg dose) produced 24.2% mean body weight reduction at 48 weeks in adults with obesity
Patients who lose the most weight on GLP-1s tend to make protein-forward food choices, stay hydrated (GLP-1s slow gastric emptying and dehydrate patients faster than they realize), prioritize sleep (sleep deprivation drives weight regain), and add some form of strength training
doi: 10.1007/s12035-015-9238-7 10
US$ 29.37
US$ 24.82
US$ 21.46
US$ 21.12
US$ 23.28
